JP2021102626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021102626A5 JP2021102626A5 JP2021040110A JP2021040110A JP2021102626A5 JP 2021102626 A5 JP2021102626 A5 JP 2021102626A5 JP 2021040110 A JP2021040110 A JP 2021040110A JP 2021040110 A JP2021040110 A JP 2021040110A JP 2021102626 A5 JP2021102626 A5 JP 2021102626A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- sodium
- brimonidine tartrate
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 60
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims description 18
- 229960001724 brimonidine tartrate Drugs 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 claims description 12
- 229960005221 timolol maleate Drugs 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000004410 intraocular pressure Effects 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 230000002411 adverse Effects 0.000 claims description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 4
- 206010006784 Burning sensation Diseases 0.000 claims description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 201000001033 conjunctival folliculosis Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
- KWLGMAGOJDKAAF-UHFFFAOYSA-M [Cl-].[Na+].O.O.O.O.O.O.O.O.O.O Chemical compound [Cl-].[Na+].O.O.O.O.O.O.O.O.O.O KWLGMAGOJDKAAF-UHFFFAOYSA-M 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 150000004688 heptahydrates Chemical class 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 239000008177 pharmaceutical agent Substances 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000004691 decahydrates Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XVNVFKZODWAQKN-UHFFFAOYSA-N phosphoric acid;heptahydrate Chemical compound O.O.O.O.O.O.O.OP(O)(O)=O XVNVFKZODWAQKN-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023062494A JP2023086773A (ja) | 2015-03-19 | 2023-04-07 | ブリモニジン及びチモロールの固定用量合剤 |
| JP2025049992A JP2025100564A (ja) | 2015-03-19 | 2025-03-25 | ブリモニジン及びチモロールの固定用量合剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135320P | 2015-03-19 | 2015-03-19 | |
| US62/135,320 | 2015-03-19 | ||
| JP2017548997A JP7199146B2 (ja) | 2015-03-19 | 2016-03-17 | ブリモニジン及びチモロールの固定用量合剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548997A Division JP7199146B2 (ja) | 2015-03-19 | 2016-03-17 | ブリモニジン及びチモロールの固定用量合剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062494A Division JP2023086773A (ja) | 2015-03-19 | 2023-04-07 | ブリモニジン及びチモロールの固定用量合剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021102626A JP2021102626A (ja) | 2021-07-15 |
| JP2021102626A5 true JP2021102626A5 (https=) | 2022-03-04 |
Family
ID=55640942
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548997A Active JP7199146B2 (ja) | 2015-03-19 | 2016-03-17 | ブリモニジン及びチモロールの固定用量合剤 |
| JP2021040110A Pending JP2021102626A (ja) | 2015-03-19 | 2021-03-12 | ブリモニジン及びチモロールの固定用量合剤 |
| JP2023062494A Pending JP2023086773A (ja) | 2015-03-19 | 2023-04-07 | ブリモニジン及びチモロールの固定用量合剤 |
| JP2025049992A Pending JP2025100564A (ja) | 2015-03-19 | 2025-03-25 | ブリモニジン及びチモロールの固定用量合剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548997A Active JP7199146B2 (ja) | 2015-03-19 | 2016-03-17 | ブリモニジン及びチモロールの固定用量合剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062494A Pending JP2023086773A (ja) | 2015-03-19 | 2023-04-07 | ブリモニジン及びチモロールの固定用量合剤 |
| JP2025049992A Pending JP2025100564A (ja) | 2015-03-19 | 2025-03-25 | ブリモニジン及びチモロールの固定用量合剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180078500A1 (https=) |
| EP (2) | EP3270892B1 (https=) |
| JP (4) | JP7199146B2 (https=) |
| KR (1) | KR20170129823A (https=) |
| CN (1) | CN107427460A (https=) |
| AU (3) | AU2016233125A1 (https=) |
| CA (1) | CA2977825A1 (https=) |
| HK (1) | HK1246689A1 (https=) |
| WO (1) | WO2016149498A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7170436B2 (ja) * | 2017-06-28 | 2022-11-14 | 千寿製薬株式会社 | 水溶性高分子を含む点眼剤 |
| WO2019112030A1 (ja) * | 2017-12-08 | 2019-06-13 | 千寿製薬株式会社 | 水溶性高分子を含む水性液剤 |
| WO2019216395A1 (ja) * | 2018-05-11 | 2019-11-14 | 千寿製薬株式会社 | 眼科用組成物 |
| WO2019223748A1 (zh) * | 2018-05-25 | 2019-11-28 | 爱博诺德(北京)医疗科技股份有限公司 | 粘弹剂材料 |
| JP7630944B2 (ja) * | 2019-09-12 | 2025-02-18 | 千寿製薬株式会社 | ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物 |
| GR1010024B (el) * | 2020-05-06 | 2021-06-01 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη |
| WO2023086878A1 (en) | 2021-11-10 | 2023-05-19 | Visus Therapeutics, Inc. | Carbachol formulations to enhance anti-presbyopia effects |
| CN115671037A (zh) * | 2022-11-21 | 2023-02-03 | 山东诺明康药物研究院有限公司 | 一种溴莫尼定噻吗洛尔pH敏感型原位凝胶及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003198C (en) * | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| CA2416169C (en) * | 2000-07-14 | 2008-09-23 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
| PL360707A1 (en) * | 2000-07-14 | 2004-09-20 | Allergan Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| CA2505836C (en) * | 2004-05-06 | 2013-08-27 | Alcon Inc. | Topical brimonidine tartrate formulations that lack chlorine dioxide |
| DK2377557T3 (en) | 2004-11-24 | 2017-02-06 | Meda Pharmaceuticals Inc | Compositions comprising azelastine and methods for its use |
| US20070238732A1 (en) * | 2006-04-10 | 2007-10-11 | Allergan, Inc. | Brimonidine and timolol compositions |
| WO2008024846A2 (en) * | 2006-08-25 | 2008-02-28 | Allergan, Inc. | Brimonidine and timolol compositions |
| MX2012007397A (es) * | 2009-12-22 | 2012-08-15 | Allergan Inc | Composiciones y metodos para reducir la presion intraocular. |
| HUE040283T2 (hu) * | 2010-07-29 | 2019-02-28 | Allergan Inc | Brimonidin és timolol tartalmú, tartósítószer-mentes oldatok |
| JP2014501748A (ja) | 2010-12-21 | 2014-01-23 | リコファーマ アーベー | 涙代用物 |
| ES2818073T3 (es) * | 2013-12-24 | 2021-04-09 | Sentiss Pharma Private Ltd | Solución oftálmica de tartrato de brimonidina tópica |
| US20160331746A1 (en) * | 2015-05-12 | 2016-11-17 | University Of South Florida | Sortilin-Binding Small Molecules for Increasing Glucose Uptake |
-
2016
- 2016-03-17 KR KR1020177029678A patent/KR20170129823A/ko not_active Ceased
- 2016-03-17 HK HK18106462.6A patent/HK1246689A1/zh unknown
- 2016-03-17 EP EP16712655.6A patent/EP3270892B1/en active Active
- 2016-03-17 EP EP24168727.6A patent/EP4420726A3/en not_active Withdrawn
- 2016-03-17 CA CA2977825A patent/CA2977825A1/en active Pending
- 2016-03-17 WO PCT/US2016/022874 patent/WO2016149498A1/en not_active Ceased
- 2016-03-17 JP JP2017548997A patent/JP7199146B2/ja active Active
- 2016-03-17 AU AU2016233125A patent/AU2016233125A1/en not_active Abandoned
- 2016-03-17 CN CN201680015524.5A patent/CN107427460A/zh active Pending
- 2016-03-17 US US15/558,515 patent/US20180078500A1/en not_active Abandoned
-
2021
- 2021-03-12 JP JP2021040110A patent/JP2021102626A/ja active Pending
- 2021-06-04 AU AU2021203665A patent/AU2021203665A1/en not_active Abandoned
- 2021-12-16 US US17/644,719 patent/US20220370346A1/en not_active Abandoned
-
2023
- 2023-04-07 JP JP2023062494A patent/JP2023086773A/ja active Pending
- 2023-07-24 AU AU2023208076A patent/AU2023208076A1/en not_active Abandoned
-
2025
- 2025-03-25 JP JP2025049992A patent/JP2025100564A/ja active Pending
- 2025-06-17 US US19/240,454 patent/US20250387325A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021102626A5 (https=) | ||
| US20220218669A1 (en) | Compositions and methods for non-surgical treatment of ptosis | |
| US10792288B2 (en) | Preservative free brimonidine and timolol solutions | |
| KR101421519B1 (ko) | 자기 보존 수성 약제학적 조성물 | |
| EP3270892B1 (en) | Fixed dose combination of brimonidine and timolol | |
| JP2019507758A5 (https=) | ||
| AU2011274245B2 (en) | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease | |
| US20190008832A1 (en) | Compositions for the treatment of presbyopia | |
| JP7787129B2 (ja) | 眼科組成物 | |
| MX2014013444A (es) | Composiciones oftalmicas con retención y proteccion de desecación mejoradas. | |
| KR20140102701A (ko) | 각결막 보호제 또는 각결막 장해 억제제 | |
| US4197301A (en) | Topical ophthalmic use of Prazosin | |
| JP4718160B2 (ja) | 眼科用組成物 | |
| KR20220068131A (ko) | 세티리진 및 토코페솔란을 포함하는 안과용 조성물 | |
| JP7534129B2 (ja) | 多成分配合点眼剤 | |
| HK40028636A (en) | Oxymetazoline for Topical Ophthalmic Administration and Uses Thereof | |
| HK1191223B (en) | Compositions and methods for non-surgical treatment of ptosis | |
| HK1191223A (en) | Compositions and methods for non-surgical treatment of ptosis | |
| HK40005358A (en) | Eye-drop composition for lowering intraocular pressure |